PAIN THERAPEUTICS, INC.
SAVA US14817C1071
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 516% | -38% | -19% | -89% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Cook Robert Christopher CLO |
2.91 USD |
13,725 Bought |
39,940 USD |
30/09/2025 | 30/09/2025 |
| Cook Robert Christopher CLO |
2.91 USD |
13,725 Bought |
39,940 USD |
30/09/2025 | 30/09/2025 |
| Barry Richard CEO |
2.28 USD |
7,172 Bought |
16,352 USD |
22/09/2025 | 22/09/2025 |
| Barry Richard CEO |
2.29 USD |
46,908 Bought |
107,419 USD |
18/09/2025 | 19/09/2025 |
| Barry Richard CEO |
2.25 USD |
400 Bought |
900 USD |
18/09/2025 | 19/09/2025 |
| Barry Richard CEO |
2.24 USD |
185,233 Bought |
414,922 USD |
18/09/2025 | 18/09/2025 |
| Barry Richard CEO |
2.13 USD |
5,400 Bought |
11,502 USD |
18/09/2025 | 18/09/2025 |
| Schoen Eric CFO |
3.86 USD |
59,800 Sold |
230,828 USD |
29/11/2024 | 29/11/2024 |
| Kupiec James William CMO |
3.87 USD |
4,000 Sold |
15,480 USD |
29/11/2024 | 29/11/2024 |
| Schoen Eric CFO |
3.82 USD |
2,000 Sold |
7,640 USD |
29/11/2024 | 29/11/2024 |